ELP1 and cancer: Among the 5/30 patients (16.7%) presenting more than 1 malignancy, 4 developed secondary cancer in the radiation fields after craniospinal irradiation, compatible with histologies and delays observed in patients with sporadic MB after similar treatments, as reported elsewhere.23,24 The last extra-MB malignancy on our series (preB-ALL) preceded the treatment; its relation to ELP1 PV is not obvious given the lack of ELP1 PV reported in pediatric hemopathies so far, and the absence of 9q loss.